Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

An Overview of Landiolol (an Ultra-Short Acting ß1 Selective Antagonist) in Atrial Fibrillation

Version 1 : Received: 18 February 2024 / Approved: 19 February 2024 / Online: 19 February 2024 (11:19:58 CET)

A peer-reviewed article of this Preprint also exists.

Floria, M.; Oancea, A.F.; Morariu, P.C.; Burlacu, A.; Iov, D.E.; Chiriac, C.P.; Baroi, G.L.; Stafie, C.S.; Cuciureanu, M.; Scripcariu, V.; Tanase, D.M. An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation. Pharmaceutics 2024, 16, 517. Floria, M.; Oancea, A.F.; Morariu, P.C.; Burlacu, A.; Iov, D.E.; Chiriac, C.P.; Baroi, G.L.; Stafie, C.S.; Cuciureanu, M.; Scripcariu, V.; Tanase, D.M. An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation. Pharmaceutics 2024, 16, 517.

Abstract

Landiolol is an ultra-short-acting, selective ß1- adrenergic receptor blocker that was originally approved by Japan for the treatment of intraoperative tachyarrhythmias. It has gained attention for its use in the management of tachyarrhythmias and perioperative tachycardia, especially atrial fibrillation for both cardiac and non-cardiac surgeries. It can be the ideal agent for heart rate control due to its high β1‐selectivity, the potent negative chronotropic effect, a limited negative inotropic potential, and an ultrashort elimination half‐life (around 4 min); moreover, it may have a potential therapeutic effect for sepsis and pediatric patients. Landiolol seems to be superior to other short‐acting and selective beta‐blockers such as esmolol. This review aims to provide a comprehensive overview of landiolol, a new ultra-short-acting ß1 selective antagonist, including its pharmacology, clinical applications, efficacy, safety profile, and future directions in research and clinical data.

Keywords

landiolol; atrial fibrillation; beta-blockers; perioperative tachyarrhythmias; cardiac surgery; arrhythmias

Subject

Medicine and Pharmacology, Cardiac and Cardiovascular Systems

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.